ClinicalTrials.gg
Not yet recruitingNCT07720635Halo-1Updated Jul 23, 2026

A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease

A Phase 3 interventional study of KHN939 and Placebo in Thyroid Eye Disease, sponsored by Beijing Kanghong Biological Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Beijing Kanghong Biological Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Planned enrollment
24th of 45
60 · median 64
Started
2026
with 10 others
Phase 3
13 of 55
4 open now
Primary completion
2027-04
later than 10 of 27 live
Registered
53rd of 55
by date
Lead sponsor
2 of 55
Beijing Kanghong Biological Medicine Co., Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 24th largest by planned enrollment of the 45 interventional ones that give a count, is one of 11 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 10 of the 27 other live ones, and was the 53rd registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with moderate-to-severe active thyroid eye disease (TED). Approximately 60 participants who meet the study eligibility criteria will be randomized in a 2:1 ratio (stratified by smoking status) to receive 8 infusions of KHN939 or placebo q3W.

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-70 years (inclusive) at the time of signing the form (ICF), male or female
  2. Weight between 45 kg and 100 kg
  3. Diagnosed with moderate-to-severe active TED:

    • Proptosis ≥18 mm, accompanied by at least one of the following: (a) eyelid retraction ≥2 mm; (b) moderate to severe soft tissue involvement; (c) intermittent or continuous diplopia
    • CAS ≥ 3 points
    • Duration of active TED symptoms ≤12 months prior to screening (documented by patient history or medical records)
  4. Female participants of must have a negative serum pregnancy test during screening and agree to use an effective method of from screening until 90 days after the last dose of the study drug. (Note: Women of non-childbearing potential, defined as surgically sterile or , are exempt.) Male participants must agree to use birth control from screening until at least 90 days after the dose of study drug.
  5. Able to comply with all protocol-required procedures, examinations, and symptom reporting.

Exclusion criteria

Exclusion Criteria:

  1. Known to any component of the study drug formulation, or prior hypersensitivity to any monoclonal antibodies
  2. Proptosis at Day 1 (pre-dose) that has decreased by ≥2 mm relative to screening
  3. CAS at Day 1 (pre-dose) that has decreased by ≥2 points relative to screening
  4. Ocular conditions:

    • Prior or investigator-assessed diagnosis of dysthyroid optic neuropathy (DON) at screening
    • Corneal involvement in the study eye without improvement after appropriate treatment
    • Prior orbital radiotherapy or surgery for TED in the study eye (including orbital decompression, strabismus correction, eyelid correction)
    • Requires immediate or planned ophthalmic surgical intervention during the study period
    • Has any pre-existing ocular condition (e.g., high myopia, anticipated cataract surgery) that, as determined by the investigator, would preclude study participation or complicate the interpretation of study results;
  5. Prior/concomitant treatments:

    • Cumulative use for TED ≥1 g methylprednisolone equivalent. [Note: Participants receiving \<1 g and discontinued ≥30 days prior to screening are eligible]
    • Corticosteroid use within 30 days of screening (except topical, intranasal, inhaled, or intra-articular)
    • Periorbital/periocular corticosteroid injection within 90 days of screening
    • Corticosteroid or non-steroidal eye drops within 7 days of screening
    • Oral or IV non-steroidal immunosuppressants within 90 days of screening
    • Prior anti-CD20 antibody, IL-6 receptor antibody, teprotumumab, or teprotumumab N01 at any time
    • Any other TED treatment (including IGF-1R or TSHR-targeting biologics) at any time
    • Need for selenium or vitamin supplementation for TED treatment from 21 days pre-dose through study end (multivitamins are permitted)
  6. Medical history/conditions:

    • Medical conditions that contraindicate study drug use, including: suspected or confirmed inflammatory bowel disease (IBD), coagulopathy, Cerebrovascular accident (CVA) or (TIA) within 180 days, acute myocardial infarction (MI), unstable angina, or CABG/PCI within 180 days, severe arrhythmia, or severe systemic infection
    • (treated or untreated) within 5 years prior to screening, except for the following cured or non- conditions: cutaneous squamous cell carcinoma (SCC) or basal cell carcinoma (BCC), cervical or prostate carcinoma in situ (CIS), papillary thyroid carcinoma
    • Uncontrolled diabetes ( ≥8.0% at screening, or initiation of a new diabetes medication, or a >10% dose adjustment to an existing diabetes medication within 60 days prior to screening)
    • Poorly controlled thyroid function: defined as FT3 or FT4 deviating ≥50% from local laboratory normal range (≥1.5× or ≤0.5×LLN)
    • Uncontrolled hypertension: defined as SBP ≥160 mmHg or DBP ≥100 mmHg; renal artery stenosis; or other evidence of clinically unstable blood pressure
    • 12-lead with a heart rate \<50 or >100 bpm and evidence of active cardiac disease; or any screening ECG abnormality that, in the investigator's opinion, confounds subsequent interpretation, particularly >450 ms in males or >470 ms in females
  7. Laboratory exclusions at screening:

    • (ALT) >3 × ULN
    • Aspartate aminotransferase (AST) >3 × ULN
    • Serum creatinine(Cr) ≥1.5 × ULN, or (GFR) \<30 mL/min/1.73 m² (MDRD formula)
  8. ear disease, prior ear surgery, hearing impairment, or abnormal pure-tone audiometry (defined as a mean bone conduction threshold ≥25 dB at 0.5, 1, 2, 4 kHz, or ≥40 dB at any frequency)
  9. Positive for with HBV-DNA >1000 IU/mL or currently receiving anti-HBV therapy; positive for antibody or antibody; or active syphilis
  10. Participation in any drug, vaccine, or device clinical trial within 3 months prior to screening, or currently within follow-up or within 5 half-lives of another study
  11. Female subjects who are pregnant or lactating
  12. Any other condition deemed by the investigator as inappropriate for study participation
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    KHN939 20 mg/kg

    8 infusions of KHN939 q3W for a total of 21 weeks

    Drug: KHN939

  • Placebo comparator
    Placebo

    8 infusions of placebo q3W for a total of 21 weeks

    Drug: Placebo

Interventions

  • DrugKHN939

    Intravenous (IV) infusion: 20 mg/kg every 3 weeks (Q3W) for a total of 8 doses over 21 weeks

  • DrugPlacebo

    Intravenous (IV) infusion: placebo every 3 weeks (Q3W) for a total of 8 doses over 21 weeks

06

What researchers measure

Primary outcomes

  1. The proptosis responder rate of the study eye

    Defined as percentage of subjects with a ≥ 2mm reduction from Baseline in proptosis in the study eye, without deterioration \[≥ 2 mm increase\] of proptosis in the non-study eye at Week 24. Proptosis assessment: amount of protrusion of the eye from the orbital rim measured by Hertel exophthalmometer.

    Time frame: Week 24

Secondary outcomes

  1. Proptosis responder rate in the study eye

    See primary outcome measure description for details.

    Time frame: Week 12

  2. Overall responder rate in the study eye

    Defined as study eye CAS reduced ≥2 points from baseline AND proptosis reduced ≥2 mm from baseline,without deterioration (without deterioration: CAS increase \<2 points AND proptosis increase \<2 mm) in the fellow eye.

    Time frame: week 12, week 24

  3. Change from baseline in proptosis measurement of the study eye

    See primary outcome measure description for details.

    Time frame: week 12, week 24

  4. Change in Quality of Life (GO-QoL) Scores

    The GO-QoL is a 16-item self-administered questionnaire divided into 2 subsets and used to assess the perceived effects of TED by the subjects on (i) their daily physical activity as it relates to visual function, and (ii) psychosocial functioning. The range of the GO-QoL overall transformed scores is 0 to 100, where higher values correspond to better quality of life.

    Time frame: week 12, week 24

  5. Change from baseline in Clinical Activity Score (CAS) in the study eye

    The CAS, based on the 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amendment, was used to evaluate clinical activity. The CAS ranges from 0 to 7, where higher scores indicate greater disease activity (worse outcome).

    Time frame: week 12, week 24

  6. Treatment response rate in the study eye

    Treatment response rate in the study eye (treatment response defined as meeting ≥2 of the following 4 criteria: (a) palpebral width reduction ≥2 mm; (b) ≥1 point reduction in any of the 5 CAS inflammatory items (eyelid erythema, eyelid edema, conjunctival erythema, conjunctival edema, caruncle swelling); (c) proptosis reduction ≥2 mm; (d) ocular motility improvement ≥8°; with no worsening in the contralateral eye).

    Time frame: week 12, week 24

  7. Change from baseline in diplopia score

    Diplopia will be evaluated using the Gorman Subjective Diplopia Scale. The total score ranges from a minimum value of 0 to a maximum value of 3 (0 = no diplopia; 1 = intermittent diplopia; 2 = inconstant diplopia; 3 = constant diplopia). Higher scores mean a worse outcome (more severe diplopia condition).

    Time frame: week 12, week 24

  8. Change from Baseline in Diplopia Questionnaire (DQ) Score

    The Diplopia Questionnaire (DQ) will be used to evaluate the severity and impact of diplopia. Total scores range from 0 to 100, with higher scores indicating greater symptom severity and a more significant negative impact on daily life (representing a worse outcome).

    Time frame: Week 12, Week 24

  9. Percentage of subjects with a CAS value of 0 or 1 in the study eye

    Time frame: week 12, week 24

  10. Proptosis responder rate in the non-study eye

    Time frame: week 12, week 24

  11. Change from baseline in proptosis measurement in the non-study eye

    Time frame: week 12, week 24

Other outcomes

  1. Change from baseline in ocular motility of the study eye

    Time frame: week 12, week 24

  2. The number, incidence, severity, and relevance to study drugs or treatments of all ocular and other systemic AEs, TEAEs, AESIs, and SAEs

    Time frame: From the Screening period through study completion, with each participant completing all study visits over approximately 28 weeks, comprising a Screening Period (up to 4 weeks), a Treatment Period (21 weeks), and a Safety Follow-up Period (3 weeks).

  3. Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAbs)

    Time frame: Up to Week 24

  4. Serum Drug Concentration

    Serum drug concentrations will be collected at the following scheduled time points: * Pre-dose (within 1 hour before infusion) and end-of-infusion (within 5 minutes after infusion completion) at Dose 1 (Week 0/Day 1), Dose 2 (Week 3), Dose 3 (Week 6), and Dose 5 (Week 12) * A single sample at Week 1 (Day 8) * A single sample at Week 24 or at early termination Serum concentration data from all sampling time points will be used to develop a population pharmacokinetic (PopPK) model and characterize the pharmacokinetics of KHN939.

    Time frame: Pre-dose and end-of-infusion at Doses 1, 2, 3, and 5, with additional samples at Week 1 and Week 24 (or early termination), up to Week 24

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 22, 2026
StartEst.
Aug 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jun 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07720635
Lead sponsor
Beijing Kanghong Biological Medicine Co., Ltd.
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Aug 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Zhili Niu
Contact
niuzhili@cnkh.com
+86-028-87516260

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion